The article, titled “The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial,” details the results of a single-arm, global ...

In the assessment of 12-month price targets, analysts unveil insights for Y-mAbs Therapeutics, presenting an average target ...

Notably, the treatment demonstrated clinical efficacy in patients previously treated with anti-GD2 antibodies. The safety profile was manageable, with most adverse effects being infusion-related.

Hu14.18 is a humanised anti-GD2 monoclonal antibody that is being tested in a phase 2 trial as an add-on to standard induction chemotherapy for the treatment of newly diagnosed high-risk ...

Neuroblastoma, an aggressive malignancy originating from neural crest cells, accounts for 15% of cancer-related deaths in children. Treatment strategies include systemic chemotherapy, radiation or ...

GPA33 antigen (colorectal cancer); GD2 antigen (neuroblastoma); and the HER2/neu receptor (breast cancer). Illustration of three-step DOTA-PRIT based on targeting with an IgG-scFv bispecific antibody ...

The report delivers a comprehensive analysis of global biologics sales. Covering cancer antibodies, non-TNF inflammatory mAbs, biosimilars, gene therapy, RNA-based drugs, and more, the report provides ...